[
  {
    "ts": null,
    "headline": "U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma",
    "summary": "Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted (6-2) in favor of the benefit-risk profile of single-agent DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). An application for the approval of DARZALEX FASPRO® for adult patients with HR-SMM was submitted to the FDA in November 2024.",
    "url": "https://finnhub.io/api/news?id=c10d3e935f1da769afe8a3b36ecf11a8d40b61fa4022a0abe4b2353c8419d36b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747779660,
      "headline": "U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma",
      "id": 134628232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted (6-2) in favor of the benefit-risk profile of single-agent DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). An application for the approval of DARZALEX FASPRO® for adult patients with HR-SMM was submitted to the FDA in November 2024.",
      "url": "https://finnhub.io/api/news?id=c10d3e935f1da769afe8a3b36ecf11a8d40b61fa4022a0abe4b2353c8419d36b"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Tweedy Browne Portfolio - Q1 2025 Update",
    "summary": "Tracking Tweedy Browne Portfolio - Q1 2025 Update",
    "url": "https://finnhub.io/api/news?id=b56a1197ba3557ed11605f018678b006950461bd3eaab99f2f9c8e953eefbdb4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747771331,
      "headline": "Tracking Tweedy Browne Portfolio - Q1 2025 Update",
      "id": 134620526,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b56a1197ba3557ed11605f018678b006950461bd3eaab99f2f9c8e953eefbdb4"
    }
  },
  {
    "ts": null,
    "headline": "J&J Says FDA Advisory Panel Favors Benefit-Risk Profile of Darzalex Faspro in Myeloma Treatment",
    "summary": "J&J Says FDA Advisory Panel Favors Benefit-Risk Profile of Darzalex Faspro in Myeloma Treatment",
    "url": "https://finnhub.io/api/news?id=73e8398f321ff127b9afd3cb532b8f702c784e51f153a98550298bb317a3c41c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747766820,
      "headline": "J&J Says FDA Advisory Panel Favors Benefit-Risk Profile of Darzalex Faspro in Myeloma Treatment",
      "id": 134633143,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "J&J Says FDA Advisory Panel Favors Benefit-Risk Profile of Darzalex Faspro in Myeloma Treatment",
      "url": "https://finnhub.io/api/news?id=73e8398f321ff127b9afd3cb532b8f702c784e51f153a98550298bb317a3c41c"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) RBC Capital Markets Global Healthcare Conference",
    "summary": "Johnson &amp; Johnson (NYSE:JNJ) RBC Capital Markets Global Healthcare Conference May 20, 2025 1:35 PM ETCorporate ParticipantsJoe Wolk - EVP, Chief...",
    "url": "https://finnhub.io/api/news?id=74bf315e087a1a7e595c1e798036a55ca2777247c2180cf6c5e8d2c5ac9f4553",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747753855,
      "headline": "Johnson & Johnson (JNJ) RBC Capital Markets Global Healthcare Conference",
      "id": 134618698,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson &amp; Johnson (NYSE:JNJ) RBC Capital Markets Global Healthcare Conference May 20, 2025 1:35 PM ETCorporate ParticipantsJoe Wolk - EVP, Chief...",
      "url": "https://finnhub.io/api/news?id=74bf315e087a1a7e595c1e798036a55ca2777247c2180cf6c5e8d2c5ac9f4553"
    }
  },
  {
    "ts": null,
    "headline": "Transcript : Johnson & Johnson Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 01",
    "summary": "Presenter SpeechShagun Singh Chadha Hello, everyone. I am Shagun Singh, Senior Research Analyst at RBC. And I'm very happy to host the next session with Johnson & Johnson. Joining us from the",
    "url": "https://finnhub.io/api/news?id=124f6229ae3e21f9876803f4b8347b9a66650f5ade72680ee59987d33c7b4663",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747751723,
      "headline": "Transcript : Johnson & Johnson Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 01",
      "id": 134615154,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Presenter SpeechShagun Singh Chadha Hello, everyone. I am Shagun Singh, Senior Research Analyst at RBC. And I'm very happy to host the next session with Johnson & Johnson. Joining us from the",
      "url": "https://finnhub.io/api/news?id=124f6229ae3e21f9876803f4b8347b9a66650f5ade72680ee59987d33c7b4663"
    }
  },
  {
    "ts": null,
    "headline": "Apple or America? The iPhone Maker Now Has a Better Credit Rating Than the U.S.",
    "summary": "Apple or America? The iPhone Maker Now Has a Better Credit Rating Than the U.S.",
    "url": "https://finnhub.io/api/news?id=074621cd6b3fb06c8eff875321130607572acc406e77707c448a86ec2d15b971",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747748700,
      "headline": "Apple or America? The iPhone Maker Now Has a Better Credit Rating Than the U.S.",
      "id": 134612538,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Apple or America? The iPhone Maker Now Has a Better Credit Rating Than the U.S.",
      "url": "https://finnhub.io/api/news?id=074621cd6b3fb06c8eff875321130607572acc406e77707c448a86ec2d15b971"
    }
  },
  {
    "ts": null,
    "headline": "J&J subsidiary ordered to pay $147M for violating antitrust rules",
    "summary": "A jury found that Biosense Webster withheld services to hospitals using reprocessed catheters.",
    "url": "https://finnhub.io/api/news?id=8bf5d4352c80387d47e58d97f09a02528a2d4adfa45305c0b3a86a2040b7ef93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747736211,
      "headline": "J&J subsidiary ordered to pay $147M for violating antitrust rules",
      "id": 134628233,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "A jury found that Biosense Webster withheld services to hospitals using reprocessed catheters.",
      "url": "https://finnhub.io/api/news?id=8bf5d4352c80387d47e58d97f09a02528a2d4adfa45305c0b3a86a2040b7ef93"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q1 2025 Commentary",
    "summary": "The Portfolio returned 1.36% (gross) and the MSCI World Health Care Index SM returned 5.29%.",
    "url": "https://finnhub.io/api/news?id=62b609fa1d5756badcdc2024a29cd0511dca54f3d6b9f9baa7ca9b6096bc8b15",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747732200,
      "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q1 2025 Commentary",
      "id": 134608635,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1479272648/image_1479272648.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The Portfolio returned 1.36% (gross) and the MSCI World Health Care Index SM returned 5.29%.",
      "url": "https://finnhub.io/api/news?id=62b609fa1d5756badcdc2024a29cd0511dca54f3d6b9f9baa7ca9b6096bc8b15"
    }
  }
]